Importer of Controlled Substances Application: Benuvia Operations, LLC
Published Date: 11/26/2025
Notice
Summary
Benuvia Operations, LLC wants to become an official importer of some powerful controlled substances like Ibogaine and Tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by December 26, 2025. This move could shake up the import scene and means Benuvia might soon handle these substances legally, with all eyes on the deadline!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Benuvia applied to import listed controlled drugs
Benuvia Operations, LLC applied on October 2, 2025 to be registered as an importer of several controlled substances, including Schedule I drugs (for example, Ibogaine, MDMA, DMT, mescaline, and tetrahydrocannabinols) and a Schedule II dronabinol oral solution. If registered, the company would be authorized to import those listed substances as specified in the application.
Import authorization excludes finished commercial dosage forms
The notice states authorization will be limited to importing bulk active pharmaceutical ingredients, dosage forms, and samples for product development and customer support, and will not extend to importing FDA-approved or non‑approved finished dosage forms for commercial sale. Applicants whose commercial business depends on importing finished dosage forms would not receive that authority under this registration.
Stakeholders can comment or request hearing
Registered bulk manufacturers of the affected drug classes and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before December 26, 2025. Comments must be submitted through Regulations.gov and hearing requests must be sent to the DEA addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-21172, Uniform Administrative Requirements, Cost Principles, and Audit Requirements
The Office of Management and Budget just released the 2025 Compliance Supplement, updating rules on how federal money is managed, spent, and audited. This affects anyone handling federal awards and applies to audits for periods after June 30, 2024. You’ve got until January 26, 2026, to send in your comments to help shape next year’s guidance—so don’t miss out!
Next: 2025-21174, Bulk Manufacturer of Controlled Substances Application: Irvine Labs, Inc.
Irvine Labs, Inc. wants to become a big-time maker of marijuana and related substances for research. People already registered or interested can share their thoughts or ask for a hearing by January 26, 2026. This move could boost research supplies but won’t affect other drug activities or costs right now.